Francesco D'Amico

Prof. Francesco D'Amico

orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2006 in Journal of Hepatology
Verified
Journal Article
Closed access
Umberto CilloUmberto Cillo
Umberto Cillo
Alessandro VitaleAlessandro Vitale
Alessandro Vitale
FGFrancesco Grigoletto
Francesco Grigoletto
FFFabio Farinati
Fabio Farinati
ABAlberto Brolese
Alberto Brolese
DDDavide Francesco D'Amico
Davide Francesco D'Amico

1 January 2004 in Journal of Hepatology
Verified
Journal Article
Closed access
Umberto CilloUmberto Cillo
Umberto Cillo
MBMarco Bassanello
Marco Bassanello
Alessandro VitaleAlessandro Vitale
Alessandro Vitale
FGFrancesco A Grigoletto
Francesco A Grigoletto
PBPatrizia Burra
Patrizia Burra
DDDavide Francesco D'Amico
Davide Francesco D'Amico

29 September 2009 in Liver Transplantation
Verified
Journal Article
Open access
PDF file
FDFrancesco D'Amico
Francesco D'Amico
MSMyron Schwartz
Myron Schwartz
Alessandro VitaleAlessandro Vitale
Alessandro Vitale
PTParissa Tabrizian
Parissa Tabrizian
SRSasan Roayaie
Sasan Roayaie
Umberto CilloUmberto Cillo
Umberto Cillo
The up-to-seven (Up-to-7) criteria [with 7 being the sum of the size and number of tumors for any given hepatocellular carcinoma (HCC)] have been recently proposed to identify potential candidates for liver transplantation (LT) among patients exceeding the Milan criteria. The aim of this study was to compare the ability of the available pathologic staging systems (the Milan, University of California San Francisco, and Up-to-7 criteria) to predict recurrence. A study population of 479 HCC transplanted patients was identified from prospectively collected databases at Mount Sinai Medical Center (New York, NY) and the University of Padua (Padua, Italy). The best pathologic staging system was identified with log rank, proportion separation index (PSEP), and Cox analyses. Pathologic tumor characteristics (tumor number, tumor size, sum of diameters, macroscopic and microscopic vascular invasion, and grading) were then tested by univariate and multivariate Cox analyses in the prognostic subgroups within and beyond the calculated criteria. The Up-to-7 criteria performed as the best pathologic staging system, the calculated 1-, 3-, and 5-year recurrence probabilities being 4%, 8%, and 14% within the criteria (n = 355) and 22%, 45%, 51% beyond the criteria (n = 124; P < 0.0001) and the calculated PSEP being 0.27 (95% confidence interval = 0.23-0.31). In multivariate analysis, only biological variables (vascular invasion and tumor grade) significantly predicted recurrence beyond the Up-to-7 criteria. A 3-stage pathologic staging system with a potential to be applied in the preoperative setting was thus created: within the Up-to-7 criteria (recurrence rate = 8%), beyond the Up-to-7 criteria without macrovascular invasion and poorly differentiated grade (recurrence rate = 24%), and beyond the Up-to-7 criteria with macrovascular invasion and/or poorly differentiated grade (recurrence rate = 45%). In conclusion, HCC patients within the pathologic Up-to-7 criteria were associated with a low risk of recurrence after LT. Beyond these criteria, however, a significant proportion of patients with a good HCC biological profile had an acceptable risk of recurrence. Liver Transpl 15:1278–1287, 2009. © 2009 AASLD.

26 March 2007 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
Umberto CilloUmberto Cillo
Umberto Cillo
Alessandro VitaleAlessandro Vitale
Alessandro Vitale
FGF. Grigoletto
F. Grigoletto
Enrico GringeriEnrico Gringeri
Enrico Gringeri
FDFrancesco D'Amico
Francesco D'Amico
DDD. F. D'Amico
D. F. D'Amico
This prospective study analyzed the dropout probability and intention-to-treat survival rates of patients with hepatocellular carcinoma (HCC) selected and treated according to our policy before liver transplantation (LT), with particular attention to those exceeding the Milan criteria. Exclusion criteria for LT were macroscopic vascular invasion, metastases, and poorly differentiated disease at percutaneous biopsy. A specific multi-modal adjuvant algorithm was used to treat HCC before LT. A total of 100 HCC patients were listed for LT: 40 exceeded the Milan criteria in terms of nodule size and number (MILAN OUT) either at listing or in list, while 60 patients continued to meet the criteria (MILAN IN). The Milan criteria did not prove to be a significant predictor of dropout probability or survival rates using Cox's analysis. Cumulative dropout probability at 6 and 12 months was 0% and 4% for MILAN OUT, and 6% and 11% for MILAN IN. The intention-to-treat survival rates at 1 and 3 years were 95% and 85% in MILAN OUT, and 84% and 69% in MILAN IN. None of the 68 transplanted patients had recurrent HCC after a median 16-month follow-up (0–69 months). In conclusion, LT may be effective for selected, aggressively-treated HCC patients exceeding the Milan criteria.

1 August 2003 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
ACAntonino Cavallari
Antonino Cavallari
Umberto CilloUmberto Cillo
Umberto Cillo
BNBruno Nardo
Bruno Nardo
FFFranco Filipponi
Franco Filipponi
Enrico GringeriEnrico Gringeri
Enrico Gringeri
DDDavide D’aMico
Davide D’aMico
Primary dysfunction (PDF) still occurs after orthotopic liver transplantation (OLT). Celsior solution (CS) might offer some advantages over the conventional University of Wisconsin (UW) solution for organ preservation, but to date, this has not been prospectively evaluated in the context of OLT. In this prospective, randomized, multicenter, pilot study, 215 potential liver donors were enrolled and randomized. In 42 cases, the livers were unsuitable for transplantation; therefore, 173 randomized livers ultimately were implanted after perfusion and cold preservation with CS (n = 83) or UW solution (n = 90). In accord with the indications of the CS manufacturing company, total CS infusion volume was 90 mL/kg, greater than that of UW solution (60 mL/kg). The main aim of the study is to compare the prevalence of PDF between the two groups. Donor and recipient variables were similar in the two groups. Episodes of PDF were numerically lower in the CS (2.4%) than UW group (7.8%), but the difference was not statistically significant. There was a trend toward a lesser need for early re-OLT (<30 days) in the CS group (P = .0507), but again, no statistically significant difference emerged. Overall and time-differentiated postoperative deaths also were similar. One-year actuarial patient (UW, 89% v CS, 87%) and graft (UW, 83% v CS, 85%) survival rates were similar. In conclusion, CS was similar to UW solution as a preservation solution in the clinical setting of OLT at the infusion volumes described, although some theoretical advantages of CS composition suggest that CS might prove a valid alternative to UW preservation solution in multiorgan harvesting, including the liver. A study on a larger patient basis is needed.

9 March 2010 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Alessandro VitaleAlessandro Vitale
Alessandro Vitale
FDFrancesco D'Amico
Francesco D'Amico
AFAnna Chiara Frigo
Anna Chiara Frigo
FGFrancesco Grigoletto
Francesco Grigoletto
ABAlberto Brolese
Alberto Brolese
Umberto CilloUmberto Cillo
Umberto Cillo